Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

New facility to support advancements in molecular diagnostics, rare disease research, and industrial microbiology ...

(Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its ...

Colossal Biosciences wants to bring back the woolly mammoth and has raised $200 million at a $10.2 billion valuation to do it ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...

CRISPR screening libraries are collections of carefully designed single-guide RNAs (sgRNAs) that allow researchers to ...

Mars is a strange place and any humans born there are bound to look radically different over thousands or even hundreds of ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...